GlassScriptPhysician profile
Steven Madsen
NPI 1861925356
$10,894.46
in general payments reported to CMS, 2019-2025
23 companies · $4,204 in 2025
The $4,204 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.13 · 2020: $214 · 2021: $1,466 · 2022: $1,088 · 2023: $1,007 · 2024: $2,841 · 2025: $4,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,842 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,842.45 |
| Education | $209.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,228.15 | 2020-2025 | |
| Janssen Biotech, INC. | $927.51 | 2023-2025 | Tremfya |
| Pfizer INC. | $919.00 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $736.24 | 2019-2025 | |
| Leo Pharma INC. | $728.67 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $624.54 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $471.64 | 2023-2025 | Zoryve |
| Genzyme Corporation | $466.20 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $464.05 | 2024-2025 | |
| Incyte Corporation | $456.43 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $337.96 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $293.82 | 2025 | Nemluvio |
| Ucb, INC. | $272.14 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $195.54 | 2023-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $159.15 | 2022-2025 | Cabtreo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $129.51 | 2023-2024 | Vtama |
| Amgen INC. | $127.74 | 2024-2025 | Otezla, Otezla |
| Kerecis Limited | $120.25 | 2021 | |
| Kyowa Kirin, INC. | $106.55 | 2021 | |
| Organon LLC | $53.67 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $29.58 | 2022-2024 | Valchlor |
| Mayne Pharma Commercial LLC | $25.18 | 2025 | |
| Botanix Sb INC | $20.94 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Madsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.